Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) EBITDA Margin (2019 - 2026)

C4 Therapeutics has reported EBITDA Margin over the past 8 years, most recently at 414.52% for Q1 2026.

  • For Q1 2026, EBITDA Margin fell 5071.0% year-over-year to 414.52%; the TTM value through Mar 2026 reached 298.96%, down 4042.0%, while the annual FY2025 figure was 292.09%, 337.0% up from the prior year.
  • EBITDA Margin for Q1 2026 was 414.52% at C4 Therapeutics, down from 186.78% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 148.06% in Q2 2024 and troughed at 1322.3% in Q2 2023.
  • A 5-year average of 556.17% and a median of 414.52% in 2026 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: tumbled -117727bps in 2022 and later surged 117424bps in 2024.
  • Year by year, EBITDA Margin stood at 1258.34% in 2022, then rose by 17bps to 1041.92% in 2023, then surged by 35bps to 675.58% in 2024, then skyrocketed by 72bps to 186.78% in 2025, then plummeted by -122bps to 414.52% in 2026.
  • Business Quant data shows EBITDA Margin for CCCC at 414.52% in Q1 2026, 186.78% in Q4 2025, and 285.39% in Q3 2025.